BPC-157 has spent nearly three years in a strange kind of regulatory purgatory — not banned outright, not approved, but sitting on an FDA restricted list that made most compounding pharmacies treat it as radioactive. That’s now changing, in fits and starts. Over the past six months, BPC-157 has moved from officially restricted, to a murky in-between status, to a real (if narrow) recommendation for a legitimate compounding pathway. It’s still not legal for a pharmacy to compound BPC-157 today. But the path to that outcome is now clearer than it’s been since 2023, and it’s worth walking through exactly where things stand.
How BPC-157 Ended Up Restricted
To understand the current moment, you need the backstory. In September 2023, the FDA placed BPC-157 and more than a dozen other peptides into “Category 2” of its Section 503A Bulk Drug Substances list — the category reserved for substances where the agency has identified “significant safety concerns,” including questions about immunogenicity, impurities, and thin human clinical data. Category 2 status effectively barred compounding pharmacies from using these peptides in patient prescriptions without risking FDA enforcement. That’s the restriction that’s defined BPC-157’s legal status for the peptide research and compounding world ever since — technically not scheduled or banned outright, but functionally off-limits for licensed pharmacy compounding.
The 2026 Reclassification
The first real crack in that wall came in February 2026, when HHS Secretary Robert F. Kennedy Jr. announced that many Category 2 peptides would be reconsidered for reclassification. On April 15, 2026, Kennedy confirmed the removal of twelve peptides from Category 2 — including BPC-157, TB-500, MOTs-c, Semax, Epitalon, and several others — after their original nominators withdrew the safety-concern nominations that had put them there in the first place. That’s an important nuance: removal from Category 2 didn’t happen because the FDA reversed a safety finding. It happened because the underlying nominations were withdrawn, clearing the technical path for reconsideration. Removal from Category 2 also does not automatically mean a substance is approved for compounding — it just means the door that had been explicitly locked is no longer explicitly locked. The substance still needs to clear a separate bar to land on the actual list of approved bulk compounding substances.
What the PCAC Just Recommended
That separate bar is where the most concrete news comes in. On July 23 and 24, 2026, the FDA’s Pharmacy Compounding Advisory Committee — an outside panel of pharmacy, academic, and industry experts that reviews compounding substances and issues non-binding recommendations to the FDA — formally voted on whether to recommend BPC-157 and six other peptides for addition to the 503A Bulk Drugs List. The vote for BPC-157 was 8 in favor, 6 opposed, and 1 abstention — a real recommendation, but not a landslide, and one that split the room. TB-500, KPV, MOTs-c, Epitalon, and Semax all received similar recommend-for-inclusion votes; a seventh candidate, Emideltide, was voted down 6-7.
During the public comment sessions, opponents argued the peptides lack sufficient clinical safety and efficacy data and that formal inclusion could be misread as an FDA safety endorsement. Supporters countered that these compounds already have long track records of use by licensed practitioners, and that formal listing would actually improve safety by bringing sourcing and quality standards under regulatory scrutiny instead of leaving the market to informal gray-channel supply. Notably, the FDA’s own scientists recommended against inclusion in each case, citing insufficient safety and characterization data — the PCAC’s committee members overruled that recommendation with their votes, which is itself a meaningful signal about how the expert panel is currently weighing patient access against open safety questions.
What Happens Next — and Why It’s Slow
A PCAC recommendation is not a rule. The committee doesn’t have the authority to approve anything; it advises the FDA, which then has to run a formal notice-and-comment rulemaking process before BPC-157 can officially join the 503A Bulk Drugs List. Legal analysts tracking the process expect that rulemaking could stretch into 2027 or beyond. In the meantime, the FDA has signaled it may apply informal “enforcement discretion” to substances PCAC recommended for inclusion — meaning the agency might choose not to prioritize enforcement against compounders using BPC-157 while the formal process plays out, without that amounting to actual legal authorization.
That gray zone matters in practice. Some state pharmacy boards aren’t waiting for federal clarity. Ohio’s Board of Pharmacy, for instance, has already issued guidance explicitly stating that Category 2 and Category 3 peptides — including BPC-157 — cannot be legally compounded under state law, and has taken enforcement action, including summary suspensions, against pharmacies that did so anyway. Other states may take a more permissive or a stricter approach, and how each state’s board responds to the PCAC recommendations remains genuinely unclear as of this writing.
Frequently Asked Questions
Is BPC-157 legal right now?
It depends what you mean by “legal.” It’s not a DEA-scheduled controlled substance, so simple possession isn’t a federal crime. It’s not FDA-approved as a drug, so it can’t legally be marketed for human treatment. And as of today, it’s still not formally authorized for pharmacy compounding, though enforcement in that gray zone varies by state and situation.
Does the PCAC vote mean my pharmacy can compound it now?
Not yet, technically. Formal addition to the 503A Bulk Drugs List requires completed FDA rulemaking, which hasn’t happened. Some enforcement discretion may apply in the interim, but that’s an informal posture, not a legal green light — and state boards can still enforce more strictly than the federal baseline.
Why did BPC-157 get restricted in the first place?
The FDA’s original 2023 Category 2 placement cited concerns about immunogenicity (immune reactions), impurities in manufacturing, and limited human clinical trial data — not a specific safety incident, but a judgment that the evidence base wasn’t strong enough to support unrestricted compounding.
How does this affect research use of BPC-157?
It doesn’t, directly. Research-use-only procurement for laboratory and academic investigation is governed by a completely separate framework than pharmacy compounding for patient prescriptions. For more on how that distinction works, see our overview of research peptide legal status and our coverage of the FDA’s 2026 warning letter enforcement wave targeting sellers who blur that line.
The Bigger Picture
BPC-157’s trajectory over the past year is a useful case study in how slowly federal drug compounding policy actually moves, even when the political winds shift in a substance’s favor. A cabinet secretary’s announcement, a formal reclassification, and a split-but-favorable expert committee vote have moved the needle — but the substance still isn’t formally authorized for compounding, and won’t be until a rulemaking process that could take years works its way through. For researchers and patients tracking this closely, the PCAC recommendation is real progress. It just isn’t the finish line.
This article is for educational purposes only and summarizes publicly available FDA and legal-industry information. It is not legal or medical advice. Regulatory status can change; consult current FDA guidance and a qualified professional before making decisions based on this information.